vs
Amphastar Pharmaceuticals, Inc.（AMPH）与STURM RUGER & CO INC（RGR）财务数据对比。点击上方公司名可切换其他公司
Amphastar Pharmaceuticals, Inc.的季度营收约是STURM RUGER & CO INC的1.2倍（$183.1M vs $151.1M），STURM RUGER & CO INC同比增速更快（3.6% vs -1.8%），Amphastar Pharmaceuticals, Inc.自由现金流更多（$24.6M vs $12.3M），过去两年STURM RUGER & CO INC的营收复合增速更高（5.1% vs 3.2%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
鲁格公司（Ruger）是总部位于美国康涅狄格州绍斯波特的枪械制造企业，除总部外，还在新罕布什尔州纽波特、北卡罗来纳州梅约丹以及亚利桑那州普雷斯科特设有生产工厂。公司由亚历山大·麦考密克·斯特姆与威廉·B·鲁格于1949年共同创立，自1969年起公开上市交易。
AMPH vs RGR — 直观对比
营收规模更大
AMPH
是对方的1.2倍
$151.1M
营收增速更快
RGR
高出5.5%
-1.8%
自由现金流更多
AMPH
多$12.3M
$12.3M
两年增速更快
RGR
近两年复合增速
3.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $151.1M |
| 净利润 | $24.4M | — |
| 毛利率 | 46.8% | 17.8% |
| 营业利润率 | 19.4% | 2.3% |
| 净利率 | 13.3% | — |
| 营收同比 | -1.8% | 3.6% |
| 净利润同比 | -35.7% | — |
| 每股收益（稀释后） | $0.51 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHRGR
| Q4 25 | $183.1M | $151.1M | ||
| Q3 25 | $191.8M | $126.8M | ||
| Q2 25 | $174.4M | $132.5M | ||
| Q1 25 | $170.5M | $135.7M | ||
| Q4 24 | $186.5M | $145.8M | ||
| Q3 24 | $191.2M | $122.3M | ||
| Q2 24 | $182.4M | $130.8M | ||
| Q1 24 | $171.8M | $136.8M |
净利润AMPHRGR
| Q4 25 | $24.4M | — | ||
| Q3 25 | $17.4M | $1.6M | ||
| Q2 25 | $31.0M | $-17.2M | ||
| Q1 25 | $25.3M | $7.8M | ||
| Q4 24 | $38.0M | — | ||
| Q3 24 | $40.4M | $4.7M | ||
| Q2 24 | $37.9M | $8.3M | ||
| Q1 24 | $43.2M | $7.1M |
毛利率AMPHRGR
| Q4 25 | 46.8% | 17.8% | ||
| Q3 25 | 51.4% | 15.1% | ||
| Q2 25 | 49.6% | 3.9% | ||
| Q1 25 | 50.0% | 22.0% | ||
| Q4 24 | 46.5% | 22.8% | ||
| Q3 24 | 53.3% | 18.5% | ||
| Q2 24 | 52.2% | 22.3% | ||
| Q1 24 | 52.4% | 21.5% |
营业利润率AMPHRGR
| Q4 25 | 19.4% | 2.3% | ||
| Q3 25 | 13.2% | -2.7% | ||
| Q2 25 | 24.2% | -15.6% | ||
| Q1 25 | 21.9% | 6.2% | ||
| Q4 24 | 24.2% | 7.8% | ||
| Q3 24 | 29.8% | 3.1% | ||
| Q2 24 | 30.3% | 6.9% | ||
| Q1 24 | 27.9% | 5.5% |
净利率AMPHRGR
| Q4 25 | 13.3% | — | ||
| Q3 25 | 9.0% | 1.2% | ||
| Q2 25 | 17.8% | -13.0% | ||
| Q1 25 | 14.8% | 5.7% | ||
| Q4 24 | 20.4% | — | ||
| Q3 24 | 21.1% | 3.9% | ||
| Q2 24 | 20.8% | 6.3% | ||
| Q1 24 | 25.1% | 5.2% |
每股收益（稀释后）AMPHRGR
| Q4 25 | $0.51 | $0.22 | ||
| Q3 25 | $0.37 | $0.10 | ||
| Q2 25 | $0.64 | $-1.05 | ||
| Q1 25 | $0.51 | $0.46 | ||
| Q4 24 | $0.74 | $0.62 | ||
| Q3 24 | $0.78 | $0.28 | ||
| Q2 24 | $0.73 | $0.47 | ||
| Q1 24 | $0.81 | $0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $92.5M |
| 总债务越低越好 | $608.7M | — |
| 股东权益账面价值 | $788.8M | $283.8M |
| 总资产 | $1.6B | $342.0M |
| 负债/权益比越低杠杆越低 | 0.77× | — |
8季度趋势，按日历期对齐
现金及短期投资AMPHRGR
| Q4 25 | $282.8M | $92.5M | ||
| Q3 25 | $276.2M | $80.8M | ||
| Q2 25 | $231.8M | $101.4M | ||
| Q1 25 | $236.9M | $108.3M | ||
| Q4 24 | $221.6M | $105.5M | ||
| Q3 24 | $250.5M | $96.0M | ||
| Q2 24 | $217.8M | $105.6M | ||
| Q1 24 | $289.6M | $115.3M |
总债务AMPHRGR
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
股东权益AMPHRGR
| Q4 25 | $788.8M | $283.8M | ||
| Q3 25 | $776.7M | $279.6M | ||
| Q2 25 | $757.5M | $289.3M | ||
| Q1 25 | $751.3M | $321.5M | ||
| Q4 24 | $732.3M | $319.6M | ||
| Q3 24 | $727.7M | $314.9M | ||
| Q2 24 | $713.3M | $321.5M | ||
| Q1 24 | $672.4M | $332.0M |
总资产AMPHRGR
| Q4 25 | $1.6B | $342.0M | ||
| Q3 25 | $1.7B | $342.3M | ||
| Q2 25 | $1.6B | $349.5M | ||
| Q1 25 | $1.6B | $379.0M | ||
| Q4 24 | $1.6B | $384.0M | ||
| Q3 24 | $1.5B | $373.5M | ||
| Q2 24 | $1.5B | $376.7M | ||
| Q1 24 | $1.6B | $385.0M |
负债/权益比AMPHRGR
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $15.5M |
| 自由现金流经营现金流 - 资本支出 | $24.6M | $12.3M |
| 自由现金流率自由现金流/营收 | 13.4% | 8.2% |
| 资本支出强度资本支出/营收 | 4.5% | 2.1% |
| 现金转化率经营现金流/净利润 | 1.35× | — |
| 过去12个月自由现金流最近4个季度 | $121.2M | $38.5M |
8季度趋势，按日历期对齐
经营现金流AMPHRGR
| Q4 25 | $32.9M | $15.5M | ||
| Q3 25 | $52.6M | $12.9M | ||
| Q2 25 | $35.6M | $14.7M | ||
| Q1 25 | $35.1M | $11.1M | ||
| Q4 24 | $29.0M | $20.0M | ||
| Q3 24 | $60.0M | $9.4M | ||
| Q2 24 | $69.1M | $18.7M | ||
| Q1 24 | $55.3M | $7.3M |
自由现金流AMPHRGR
| Q4 25 | $24.6M | $12.3M | ||
| Q3 25 | $47.2M | $7.0M | ||
| Q2 25 | $25.0M | $9.1M | ||
| Q1 25 | $24.4M | $10.0M | ||
| Q4 24 | $16.6M | $16.4M | ||
| Q3 24 | $46.2M | $2.6M | ||
| Q2 24 | $63.1M | $10.1M | ||
| Q1 24 | $46.5M | $5.6M |
自由现金流率AMPHRGR
| Q4 25 | 13.4% | 8.2% | ||
| Q3 25 | 24.6% | 5.5% | ||
| Q2 25 | 14.3% | 6.9% | ||
| Q1 25 | 14.3% | 7.4% | ||
| Q4 24 | 8.9% | 11.2% | ||
| Q3 24 | 24.1% | 2.1% | ||
| Q2 24 | 34.6% | 7.7% | ||
| Q1 24 | 27.1% | 4.1% |
资本支出强度AMPHRGR
| Q4 25 | 4.5% | 2.1% | ||
| Q3 25 | 2.8% | 4.6% | ||
| Q2 25 | 6.1% | 4.2% | ||
| Q1 25 | 6.3% | 0.8% | ||
| Q4 24 | 6.7% | 2.5% | ||
| Q3 24 | 7.2% | 5.5% | ||
| Q2 24 | 3.3% | 6.6% | ||
| Q1 24 | 5.1% | 1.3% |
现金转化率AMPHRGR
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | 8.15× | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | 1.43× | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | 1.98× | ||
| Q2 24 | 1.82× | 2.27× | ||
| Q1 24 | 1.28× | 1.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
